Reviewing Beta Bionics (BBNX) & Its Competitors

Beta Bionics (NASDAQ:BBNX) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare Beta Bionics to related companies based on the strength of its dividends, profitability, analyst recommendations, risk, earnings, institutional ownership and valuation.

Risk & Volatility

Beta Bionics has a beta of 3.44, indicating that its share price is 244% more volatile than the S&P 500. Comparatively, Beta Bionics’ competitors have a beta of 2.56, indicating that their average share price is 156% more volatile than the S&P 500.

Insider & Institutional Ownership

40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Beta Bionics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beta Bionics	$100.25 million	-$73.20 million	-8.53
Beta Bionics Competitors	$1.88 billion	$139.14 million	9.47

Beta Bionics’ competitors have higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings for Beta Bionics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	4	9	1	2.67
Beta Bionics Competitors	4273	10549	18323	829	2.46

Beta Bionics presently has a consensus price target of $23.69, indicating a potential upside of 50.91%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.29%. Given Beta Bionics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Beta Bionics is more favorable than its competitors.

Profitability

This table compares Beta Bionics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-65.31%	-27.33%	-24.28%
Beta Bionics Competitors	-278.24%	-150.08%	-21.87%

Summary

Beta Bionics beats its competitors on 7 of the 13 factors compared.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.